<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="publisher-id">TAR</journal-id><journal-id journal-id-type="hwp">sptar</journal-id><journal-title-group><journal-title>Therapeutic Advances in Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1753-4658</issn><issn pub-type="epub">1753-4666</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29439648</article-id><article-id pub-id-type="pmc">5937154</article-id><article-id pub-id-type="doi">10.1177/1753465818755091</article-id><article-id pub-id-type="publisher-id">10.1177_1753465818755091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise
endurance during constant work-rate cycling and endurance shuttle walking in
chronic obstructive pulmonary disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Maltais</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="corresp" rid="corresp1-1753465818755091"/><aff id="aff1-1753465818755091">Institut universitaire de cardiologie et de
pneumologie de Qu&#x000e9;bec, Universit&#x000e9; Laval, 2725 Chemin Sainte-Foy, Qu&#x000e9;bec, QC
G1V 4G5, Canada</aff></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>Denis</given-names></name><aff id="aff2-1753465818755091">Division of Respiratory Medicine, Department of
Medicine, Queen&#x02019;s University and Kingston General Hospital, Kingston,
Ontario, Canada</aff></contrib><contrib contrib-type="author"><name><surname>G&#x000e1;ldiz Iturri</surname><given-names>Juan Bautista</given-names></name><aff id="aff3-1753465818755091">BioCruces Health Research Institute, Barakaldo,
Spain</aff></contrib><contrib contrib-type="author"><name><surname>Kirsten</surname><given-names>Anne-Marie</given-names></name><aff id="aff4-1753465818755091">Pulmonary Research Institute at LungClinic
Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany</aff></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>Dave</given-names></name><aff id="aff5-1753465818755091">Medicines Evaluation Unit, University of
Manchester, Manchester, UK</aff></contrib><contrib contrib-type="author"><name><surname>Hamilton</surname><given-names>Alan</given-names></name><aff id="aff6-1753465818755091">Boehringer Ingelheim, Burlington, Ontario,
Canada</aff></contrib><contrib contrib-type="author"><name><surname>Tetzlaff</surname><given-names>Kay</given-names></name><aff id="aff7-1753465818755091">Boehringer Ingelheim International GmbH,
Ingelheim am Rhein, Germany, and Department of Sports Medicine, University
of T&#x000fc;bingen, T&#x000fc;bingen, Germany</aff></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Yihua</given-names></name><aff id="aff8-1753465818755091">Boehringer Ingelheim Pharmaceuticals Inc.,
Ridgefield, CT, USA</aff></contrib><contrib contrib-type="author"><name><surname>Casaburi</surname><given-names>Richard</given-names></name><aff id="aff9-1753465818755091">Los Angeles Biomedical Research Institute at
Harbor-UCLA Medical Center, Torrance, CA, USA</aff></contrib></contrib-group><author-notes><corresp id="corresp1-1753465818755091"><email>Francois.Maltais@fmed.ulaval.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>2</month><year>2018</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2018</year></pub-date><volume>12</volume><elocation-id>1753465818755091</elocation-id><history><date date-type="received"><day>9</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>4</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-1753465818755091"><title>Background:</title><p>The TORRACTO<sup>&#x000ae;</sup> study evaluated the effects of tiotropium/olodaterol
<italic>versus</italic> placebo on endurance time during constant
work-rate cycling and constant speed shuttle walking in patients with
chronic obstructive pulmonary disease (COPD) after 12 weeks of
treatment.</p></sec><sec id="section2-1753465818755091"><title>Methods:</title><p>The effects of once-daily tiotropium/olodaterol (2.5/5 and 5/5 &#x003bc;g) on
endurance time during constant work-rate cycle ergometry (CWRCE) after 6 and
12 weeks of treatment were compared with placebo in patients with COPD in a
randomized, double-blind, placebo-controlled, parallel-group clinical trial.
Endurance time during the endurance shuttle walk test (ESWT) after 6 and 12
weeks of treatment was also evaluated in a subset of patients.</p></sec><sec id="section3-1753465818755091"><title>Results:</title><p>A total of 404 patients received treatment, with 165 participating in the
ESWT substudy. A statistically significant improvement in endurance time
during CWRCE was observed after 12 weeks (primary endpoint) with
tiotropium/olodaterol 5/5 &#x000b5;g [14% (<italic>p</italic> = 0.02)] but not with
tiotropium/olodaterol 2.5/5 &#x000b5;g [9% (<italic>p</italic> = 0.14)]
<italic>versus</italic> placebo. In the ESWT substudy, a trend to
improvement in endurance time during ESWT after 12 weeks (key secondary
endpoint) was observed with tiotropium/olodaterol 5/5 &#x000b5;g [21%
(<italic>p</italic> = 0.055)] and tiotropium/olodaterol 2.5/5 &#x000b5;g [21%
(<italic>p</italic> = 0.056)] <italic>versus</italic> placebo.</p></sec><sec id="section4-1753465818755091"><title>Conclusion:</title><p>Tiotropium/olodaterol 5/5 &#x000b5;g improved endurance time during cycle ergometry
<italic>versus</italic> placebo, with a strong tendency to also improve
walking endurance time.</p><p>[<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier: NCT01525615.]</p></sec></abstract><kwd-group><kwd>bronchodilator</kwd><kwd>constant work-rate cycling</kwd><kwd>COPD</kwd><kwd>endurance shuttle walking</kwd><kwd>olodaterol</kwd><kwd>tiotropium</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-1753465818755091"><title>Introduction</title><p>Activity-related dyspnea and exercise intolerance are important features of chronic
obstructive pulmonary disease (COPD) that negatively impact on ability to perform
activities of daily living. As such, evaluating exercise tolerance is now considered
to be an essential component of disease assessment.<sup><xref rid="bibr1-1753465818755091" ref-type="bibr">1</xref></sup> Of available exercise-testing protocols, constant work-rate exercise tests,
such as cycle and treadmill endurance tests and the endurance shuttle walk test
(ESWT), are the most sensitive for detecting change in exercise capacity following
intervention (pharmacologic and nonpharmacologic).<sup><xref rid="bibr2-1753465818755091" ref-type="bibr">2</xref></sup></p><p>Over the past several years, constant work-rate cycle ergometry (CWRCE) has been used
extensively in clinical trials evaluating the efficacy of long-acting
bronchodilators in patients with COPD,<sup><xref rid="bibr2-1753465818755091" ref-type="bibr">2</xref>,<xref rid="bibr3-1753465818755091" ref-type="bibr">3</xref></sup> and is often included in
clinical development programs as a complementary assessment of efficacy, alongside
traditional assessments of lung function. There is, however, a debate regarding the
most appropriate endurance exercise testing protocol.<sup><xref rid="bibr2-1753465818755091" ref-type="bibr">2</xref>,<xref rid="bibr4-1753465818755091" ref-type="bibr">4</xref><xref rid="bibr5-1753465818755091" ref-type="bibr"/><xref rid="bibr6-1753465818755091" ref-type="bibr"/>&#x02013;<xref rid="bibr7-1753465818755091" ref-type="bibr">7</xref></sup> In this regard, there has been
recent interest in the ESWT,<sup><xref rid="bibr7-1753465818755091" ref-type="bibr">7</xref><xref rid="bibr8-1753465818755091" ref-type="bibr"/><xref rid="bibr9-1753465818755091" ref-type="bibr"/><xref rid="bibr10-1753465818755091" ref-type="bibr"/>&#x02013;<xref rid="bibr11-1753465818755091" ref-type="bibr">11</xref></sup> in some part due to a view
that field walking tests are more reflective of activities performed by patients in
everyday life.<sup><xref rid="bibr12-1753465818755091" ref-type="bibr">12</xref></sup></p><p>The TORRACTO<sup>&#x000ae;</sup> study was part of a clinical program evaluating the efficacy
and safety of tiotropium/olodaterol in patients with COPD. TORRACTO<sup>&#x000ae;</sup> was
designed to evaluate two doses of tiotropium/olodaterol (2.5/5 and 5/5 &#x000b5;g) compared
with placebo on exercise endurance time (EET) during CWRCE in patients with COPD in
a parallel-group design after 12 weeks of treatment. Secondary objectives were to
evaluate EET during the ESWT after 6 and 12 weeks of treatment with
tiotropium/olodaterol in a subset of patients.</p></sec><sec sec-type="methods" id="section6-1753465818755091"><title>Methods</title><p>TORRACTO<sup>&#x000ae;</sup> [ClinicalTrials.gov identifier: NCT01525615] was a multicenter,
multinational, randomized, double-blind, placebo-controlled, parallel-group trial to
evaluate the effects of once-daily tiotropium/olodaterol (2.5/5 and 5/5 &#x003bc;g) compared
with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD
(5/5 &#x003bc;g is the approved tiotropium/olodaterol dose). The primary evaluation of
exercise tolerance was based on EET during CWRCE, while evaluation of EET during
ESWT was conducted in a subset of patients (ESWT subgroup).</p><p>The study was conducted at 58 centers in 10 countries. The ESWT substudy was
conducted at a subset of 26 sites with experience in the ESWT; all patients at the
selected sites were asked to participate in the substudy.</p><sec id="section7-1753465818755091"><title>Patients</title><p>Patients aged 40&#x02013;75 years with a clinical diagnosis of COPD and stable airway
obstruction were included if they had postbronchodilator forced expiratory
volume in 1 s (FEV<sub>1</sub>)/forced vital capacity (FVC) &#x0003c;70% and
postbronchodilator FEV<sub>1</sub> &#x0003c;80% and &#x02a7e;30% predicted normal. Patients
were current or exsmokers with a smoking history of &#x0003e;10 pack-years. Exclusion
criteria are detailed in the <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">online supplement</ext-link>.</p></sec><sec id="section8-1753465818755091"><title>Study design</title><p>During screening, patients performed spirometry to determine study eligibility.
Eligible patients were randomized to receive one of three treatments:
tiotropium/olodaterol 2.5/5 &#x003bc;g, tiotropium/olodaterol 5/5 &#x003bc;g, or placebo, all
delivered once daily <italic>via</italic> the Respimat<sup>&#x000ae;</sup> (Boehringer
Ingelheim International GmbH, Ingelheim am Rhein, Germany) inhaler (<xref ref-type="fig" rid="fig1-1753465818755091">Figure 1</xref>).</p><fig id="fig1-1753465818755091" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Study design.</p><p><sup>*</sup>Cycle ergometry testing; <sup>$</sup>endurance shuttle walk
test; <sup>&#x02021;</sup>primary endpoint assessment.</p><p>R, randomization.</p></caption><graphic xlink:href="10.1177_1753465818755091-fig1"/></fig><p>Throughout the 12-week treatment period, trial medication was self-administered
by the patient once daily between 7 a.m. and 10 a.m.; on test days,
administration of trial medication was performed under research staff
supervision. Patients continued with inhaled corticosteroids if taken at
baseline. Open-label salbutamol (albuterol) was provided as rescue medication
throughout the study.</p><p>The study was conducted in accordance with the Declaration of Helsinki and the
International Conference on Harmonization Tripartite Guideline for Good Clinical
Practice. Before the study started, the protocol was reviewed and approved by
the Institutional Review Boards, and all patients provided written, informed
consent.</p></sec><sec id="section9-1753465818755091"><title>Pulmonary function testing</title><p>Spirometry (FEV<sub>1</sub>, FVC) was performed using standard methodology.<sup><xref rid="bibr13-1753465818755091" ref-type="bibr">13</xref></sup> FEV<sub>1</sub> and FVC measured immediately before the first dose of
trial medication at the randomization visit was <italic>a priori</italic>
defined as the pretreatment baseline. Spirometry was also performed 1 h postdose
at the randomization visit, and predose and 1 h postdose after 6 and 12 weeks of
treatment.</p></sec><sec id="section10-1753465818755091"><title>Incremental cycle ergometry and constant work-rate cycle ergometry</title><p>The specific details of both incremental cycle ergometry and CWRCE have been
described previously.<sup><xref rid="bibr14-1753465818755091" ref-type="bibr">14</xref><xref rid="bibr15-1753465818755091" ref-type="bibr"/>&#x02013;<xref rid="bibr16-1753465818755091" ref-type="bibr">16</xref></sup> During
run-in, patients performed incremental cycle ergometry to symptom limitation to
determine peak work rate (Wpeak), the highest work rate maintained for &#x02a7e;30 s.
Two CWRCE tests to symptom limitation at 75% Wpeak were performed during run-in:
the first test familiarized the patient with the exercise protocol, while the
second test &#x02a7e;4 days later was <italic>a priori</italic> defined as the
pretreatment baseline. To avoid excessively long endurance times that may be
limited by motivation rather than physiology/symptoms, patients with an
endurance time of &#x0003e;25 min in training or baseline CWRCE were not eligible for
randomization. CWRCE at weeks 6 and 12 was performed 2 h postdose. Additional
information is provided in the <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">online supplement</ext-link>.</p></sec><sec id="section11-1753465818755091"><title>Incremental and endurance shuttle walking (endurance shuttle walk test
substudy)</title><p>Patients included in the ESWT substudy performed an incremental shuttle walk test
(ISWT) 2&#x02013;4 days after the initial screening visit.<sup><xref rid="bibr17-1753465818755091" ref-type="bibr">17</xref></sup> At 2&#x02013;4 days after the baseline and training CWRCE tests, training and
baseline ESWTs were performed at a walking speed corresponding to 85% of the
peak oxygen consumption estimated from the ISWT.<sup><xref rid="bibr8-1753465818755091" ref-type="bibr">8</xref></sup> The ESWT was repeated at the same walking speed after 6 and 12 weeks of
treatment, 2 h postdose, again with a 2&#x02013;4-day separation between the CWRCE and
ESWT. Both the ISWT and ESWT were performed in an enclosed corridor on a flat
10-meter-long course. Patients who completed the highest level in the ISWT were
not eligible for the substudy because a walking speed for the ESWT could not be
established for these patients. Patients with an endurance time during the
training or baseline ESWT of &#x0003e;15 min were excluded from the ESWT substudy due
to the limited (20-min) duration of the audio used for pacing the ESWT. These
patients did continue in the main part of the study (CWRCE). Further details are
provided in the <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">online supplement</ext-link>.</p></sec><sec id="section12-1753465818755091"><title>Breathing discomfort, leg discomfort, and inspiratory capacity</title><p>During CWRCE and ESWT, patients rated intensity of breathing discomfort and leg
discomfort using the modified Borg scale<sup><xref rid="bibr18-1753465818755091" ref-type="bibr">18</xref></sup> at rest, during each 2-min interval during exercise, and at the end of
exercise. During CWRCE (but not ESWT) patients also performed an inspiratory
capacity (IC) maneuver after each rating of breathing and leg discomfort.
Immediately after completing exercise, patients were asked to identify the
primary reason for stopping exercise using a previously described questionnaire.<sup><xref rid="bibr19-1753465818755091" ref-type="bibr">19</xref></sup></p></sec><sec id="section13-1753465818755091"><title>Safety assessments</title><p>At each visit, adverse events (AEs) reported by the patient were recorded
irrespective of causality. Pulse rate and systolic and diastolic blood pressure
were measured at each clinic visit immediately prior to spirometry. Clinical
laboratory testing (hematology, blood chemistry, and urinalysis) and a resting
12-lead electrocardiogram were performed at screening and at week 12.</p></sec><sec id="section14-1753465818755091"><title>Efficacy endpoints</title><p>The primary endpoint was EET during CWRCE after 12 weeks of treatment. Owing to
the skewness of the EET data during CWRCE,<sup><xref rid="bibr20-1753465818755091" ref-type="bibr">20</xref></sup> the primary analysis was prespecified to be based on the logarithm to the
base 10 of EET during CWRCE. The key secondary endpoint was EET during ESWT
after 12 weeks of treatment (ESWT subgroup), also based on
log<sub>10</sub>-transformed data.</p><p>Other exercise-related efficacy endpoints included pre-exercise, isotime, and
end-exercise IC during CWRCE, and intensity of breathing and leg discomfort
during CWRCE and ESWT.</p><p>Isotime for each patient was defined as the minimum EET among the pretreatment
baseline, week 6, and week 12 CWRCE tests. Isovalue was defined as the value of
a specific parameter at isotime. This isovalue could be an observed value (e.g.
when it occurred at the end of exercise) or it could be determined by
interpolation between the values at the two time points immediately above and
below the isotime.</p><p>FEV<sub>1</sub> and FVC (trough and 1 h postdose) were also measured to confirm
bronchodilator efficacy.</p></sec><sec id="section15-1753465818755091"><title>Statistical analysis</title><p>Mean log<sub>10</sub> EETs from CWRCE and ESWT were analyzed using a restricted
maximum likelihood-based mixed-effects model repeated measure (MMRM) approach.
Analyses included the fixed, categorical effect of treatment, test day, and
treatment-by-test-day interaction, as well as the continuous, fixed covariates
of baseline and baseline-by-test-day interaction. The baseline covariate term
also used the logarithm to the base 10. The primary analysis was performed on
the full analysis set (i.e. all randomized patients who received at least one
dose of treatment, and who had both baseline and at least one postbaseline
measurement at or before 12 weeks for the primary efficacy endpoints).</p><p>Based on a previous trial,<sup><xref rid="bibr21-1753465818755091" ref-type="bibr">21</xref></sup> an appropriate estimate of the standard deviation for log<sub>10</sub>
EET from CWRCE was 0.206; with this standard deviation, a sample size of 130
patients per group provided 90% power to detect a 21% improvement in EET during
CWRCE.</p><p>Analyses for EET during CWRCE at 12 weeks (primary endpoint), EET during ESWT at
12 weeks (key secondary endpoint), and pre-exercise IC during CWRCE at 12 weeks
(secondary endpoint) were included in a step-down hierarchical testing strategy.
Testing strategy details are provided in the online supplement (<ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">Figure S1</ext-link>).</p><p>The same MMRM approach was adopted for all other continuous secondary endpoints.
Adjusted mean values as well as treatment contrasts were presented, together
with 95% confidence intervals. Secondary endpoints (i.e. other than EET during
ESWT and pre-exercise IC at 12 weeks) were not included in the step-down
hypothesis-testing hierarchy and are considered descriptive (nominal
<italic>p</italic> values).</p><p>All treated patients were included in the safety analyses, which were descriptive
in nature.</p></sec></sec><sec sec-type="results" id="section16-1753465818755091"><title>Results</title><sec id="section17-1753465818755091"><title>Patient disposition and baseline characteristics</title><p>A total of 404 patients were randomized and received treatment (<xref ref-type="fig" rid="fig2-1753465818755091">Figure 2</xref>), with 385
included in the full analysis set.</p><fig id="fig2-1753465818755091" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>CONSORT diagram.</p><p>CONSORT, Consolidated Standards of Reporting Trials; O, olodaterol; T,
tiotropium.</p></caption><graphic xlink:href="10.1177_1753465818755091-fig2"/></fig><p>Baseline patient characteristics for the treated set are shown in <xref ref-type="table" rid="table1-1753465818755091">Table 1</xref>. Overall, 73%
were Global Initiative for Chronic Obstructive Lung Disease stage 2, with mean
predicted normal FEV<sub>1</sub> of 58.6%.</p><table-wrap id="table1-1753465818755091" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline patient characteristics (treated set and endurance shuttle walk
test subgroup).</p></caption><alternatives><graphic xlink:href="10.1177_1753465818755091-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Treated set (<italic>n</italic> =
404)</th><th align="left" colspan="3" rowspan="1">ESWT subgroup (<italic>n</italic> =
165)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 132)</th><th align="left" rowspan="1" colspan="1">T/O 2.5/5 &#x000b5;g (<italic>n</italic> = 133)</th><th align="left" rowspan="1" colspan="1">T/O 5/5 &#x000b5;g (<italic>n</italic> = 139)</th><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 50)</th><th align="left" rowspan="1" colspan="1">T/O 2.5/5 &#x000b5;g (<italic>n</italic> = 56)</th><th align="left" rowspan="1" colspan="1">T/O 5/5 &#x000b5;g (<italic>n</italic> = 59)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">87 (65.9)</td><td rowspan="1" colspan="1">87 (65.4)</td><td rowspan="1" colspan="1">95 (68.3)</td><td rowspan="1" colspan="1">31 (62.0)</td><td rowspan="1" colspan="1">38 (67.9)</td><td rowspan="1" colspan="1">45 (76.3)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) age, years</td><td rowspan="1" colspan="1">60.8 (7.6)</td><td rowspan="1" colspan="1">61.9 (7.3)</td><td rowspan="1" colspan="1">63.1 (7.5)</td><td rowspan="1" colspan="1">61.3 (6.4)</td><td rowspan="1" colspan="1">64.2 (7.7)</td><td rowspan="1" colspan="1">65.4 (7.0)</td></tr><tr><td colspan="7" rowspan="1">Mean (SD) prebronchodilator</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, l</td><td rowspan="1" colspan="1">1.501 (0.507)</td><td rowspan="1" colspan="1">1.465 (0.526)</td><td rowspan="1" colspan="1">1.460 (0.476)</td><td rowspan="1" colspan="1">1.449 (0.430)</td><td rowspan="1" colspan="1">1.360 (0.417)</td><td rowspan="1" colspan="1">1.377 (0.425)</td></tr><tr><td colspan="7" rowspan="1">Mean (SD) postbronchodilator</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>, l</td><td rowspan="1" colspan="1">1.695 (0.522)</td><td rowspan="1" colspan="1">1.616 (0.474)</td><td rowspan="1" colspan="1">1.659 (0.504)</td><td rowspan="1" colspan="1">1.646 (0.413)</td><td rowspan="1" colspan="1">1.566 (0.419)</td><td rowspan="1" colspan="1">1.588 (0.451)</td></tr><tr><td rowspan="1" colspan="1">&#x02003; % predicted normal FEV<sub>1</sub></td><td rowspan="1" colspan="1">59.7 (12.9)</td><td rowspan="1" colspan="1">57.9 (12.9)</td><td rowspan="1" colspan="1">58.2 (12.8)</td><td rowspan="1" colspan="1">60.2 (11.5)</td><td rowspan="1" colspan="1">57.7 (12.7)</td><td rowspan="1" colspan="1">57.4 (13.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub> change from prebronchodilator, l</td><td rowspan="1" colspan="1">0.194 (0.155)</td><td rowspan="1" colspan="1">0.152 (0.224)</td><td rowspan="1" colspan="1">0.199 (0.192)</td><td rowspan="1" colspan="1">0.197 (0.154)</td><td rowspan="1" colspan="1">0.206 (0.164)</td><td rowspan="1" colspan="1">0.211 (0.109)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;FEV<sub>1</sub>/FVC, %</td><td rowspan="1" colspan="1">52.5 (10.0)</td><td rowspan="1" colspan="1">51.4 (10.5)</td><td rowspan="1" colspan="1">51.9 (10.7)</td><td rowspan="1" colspan="1">52.8 (98)</td><td rowspan="1" colspan="1">51.3 (10.0)</td><td rowspan="1" colspan="1">51.3 (11.5)</td></tr><tr><td colspan="7" rowspan="1">GOLD<sup><xref ref-type="table-fn" rid="table-fn1-1753465818755091">*</xref></sup>, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;2</td><td rowspan="1" colspan="1">99 (75.0)</td><td rowspan="1" colspan="1">92 (69.2)</td><td rowspan="1" colspan="1">104 (74.8)</td><td rowspan="1" colspan="1">39 (78.0)</td><td rowspan="1" colspan="1">40 (71.4)</td><td rowspan="1" colspan="1">44 (74.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;3</td><td rowspan="1" colspan="1">32 (24.2)</td><td rowspan="1" colspan="1">41 (30.8)</td><td rowspan="1" colspan="1">31 (22.3)</td><td rowspan="1" colspan="1">11 (22.0)</td><td rowspan="1" colspan="1">16 (28.6)</td><td rowspan="1" colspan="1">12 (20.3)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) body mass index, kg/m<sup>2</sup></td><td rowspan="1" colspan="1">26.9 (5.1)</td><td rowspan="1" colspan="1">26.8 (5.2)</td><td rowspan="1" colspan="1">27.4 (5.0)</td><td rowspan="1" colspan="1">28.2 (5.2)</td><td rowspan="1" colspan="1">27.4 (4.6)</td><td rowspan="1" colspan="1">27.7 (5.1)</td></tr><tr><td rowspan="1" colspan="1">Current smoker, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">58 (43.9)</td><td rowspan="1" colspan="1">58 (43.6)</td><td rowspan="1" colspan="1">51 (36.7)</td><td rowspan="1" colspan="1">23 (46.0)</td><td rowspan="1" colspan="1">25 (44.6)</td><td rowspan="1" colspan="1">16 (27.1)</td></tr><tr><td rowspan="1" colspan="1">Exsmoker, <italic>n</italic> (%)</td><td rowspan="1" colspan="1">74 (56.1)</td><td rowspan="1" colspan="1">75 (56.4)</td><td rowspan="1" colspan="1">88 (63.3)</td><td rowspan="1" colspan="1">27 (54.0)</td><td rowspan="1" colspan="1">31 (55.4)</td><td rowspan="1" colspan="1">43 (72.9)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) smoking history, pack-years</td><td rowspan="1" colspan="1">44.0 (22.2)</td><td rowspan="1" colspan="1">48.6 (28.1)</td><td rowspan="1" colspan="1">46.0 (22.1)</td><td rowspan="1" colspan="1">45.3 (22.8)</td><td rowspan="1" colspan="1">53.3 (31.4)</td><td rowspan="1" colspan="1">45.6 (23.6)</td></tr><tr><td colspan="7" rowspan="1">Baseline pulmonary medications,
<italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;SAMA<sup><xref ref-type="table-fn" rid="table-fn2-1753465818755091">**</xref></sup></td><td rowspan="1" colspan="1">12 (9.1)</td><td rowspan="1" colspan="1">9 (6.8)</td><td rowspan="1" colspan="1">13 (9.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;LAMA<sup><xref ref-type="table-fn" rid="table-fn3-1753465818755091">&#x02021;</xref></sup> (tiotropium)</td><td rowspan="1" colspan="1">58 (43.9)</td><td rowspan="1" colspan="1">70 (52.6)</td><td rowspan="1" colspan="1">68 (48.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;SABA<sup><xref ref-type="table-fn" rid="table-fn4-1753465818755091">&#x000a7;</xref>,$</sup>
(inhaled)</td><td rowspan="1" colspan="1">78 (59.1)</td><td rowspan="1" colspan="1">76 (57.1)</td><td rowspan="1" colspan="1">69 (49.6)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;LABA<sup><xref ref-type="table-fn" rid="table-fn3-1753465818755091">&#x02021;</xref></sup> (inhaled)</td><td rowspan="1" colspan="1">66 (50.0)</td><td rowspan="1" colspan="1">76 (57.1)</td><td rowspan="1" colspan="1">82 (59.0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Inhaled steroids</td><td rowspan="1" colspan="1">68 (51.5)</td><td rowspan="1" colspan="1">68 (51.1)</td><td rowspan="1" colspan="1">76 (54.7)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Xanthines<sup><xref ref-type="table-fn" rid="table-fn4-1753465818755091">&#x000a7;</xref></sup></td><td rowspan="1" colspan="1">11 (8.3)</td><td rowspan="1" colspan="1">13 (9.8)</td><td rowspan="1" colspan="1">13 (9.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-1753465818755091"><label>*</label><p>GOLD 1 and 4 patients were excluded from the study.</p></fn><fn id="table-fn2-1753465818755091"><label>$</label><p>All patients were provided with SABA as a rescue medication during
this study.</p></fn><fn id="table-fn3-1753465818755091"><label>&#x02021;</label><p>Patients switched to study medication during treatment period.</p></fn><fn id="table-fn4-1753465818755091"><label>&#x000a7;</label><p>Permitted during treatment period.</p></fn><fn id="table-fn5-1753465818755091"><label>**</label><p>Not permitted during treatment period.</p></fn><fn id="table-fn6-1753465818755091"><p>ESWT, endurance shuttle walk test; FEV<sub>1</sub>, forced expiratory
volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative
for Chronic Obstructive Lung Disease; LABA, long-acting
&#x003b2;<sub>2</sub>-agonist; LAMA, long-acting muscarinic antagonist;
O, olodaterol; SABA, short-acting &#x003b2;-agonist; SAMA, short-acting
muscarinic antagonist; SD, standard deviation; T, tiotropium.</p></fn></table-wrap-foot></table-wrap><p>Baseline exercise-specific patient characteristics for the treated set are shown
in <xref ref-type="table" rid="table2-1753465818755091">Table 2</xref>. Baseline
characteristics were generally well balanced across treatment groups.</p><table-wrap id="table2-1753465818755091" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Baseline incremental and constant work-rate cycle ergometry
characteristics (treated set).</p></caption><alternatives><graphic xlink:href="10.1177_1753465818755091-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Treated set (<italic>n</italic> =
404)</th></tr><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 132)</th><th align="left" rowspan="1" colspan="1">T/O 2.5/5 &#x000b5;g (<italic>n</italic> = 133)</th><th align="left" rowspan="1" colspan="1">T/O 5/5 &#x000b5;g (<italic>n</italic> = 139)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Peak work rate (SD) during incremental cycle ergometry,
W</td><td rowspan="1" colspan="1">87.8 (30.7)</td><td rowspan="1" colspan="1">86.2 (26.7)</td><td rowspan="1" colspan="1">87.0 (27.4)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) baseline EET during CWRCE, s</td><td rowspan="1" colspan="1">502.7 (258.6)</td><td rowspan="1" colspan="1">490.7 (272.4)</td><td rowspan="1" colspan="1">527.5 (279.2)</td></tr><tr><td colspan="4" rowspan="1">Mean (SD) baseline IC, l</td></tr><tr><td rowspan="1" colspan="1">&#x02003;At rest</td><td rowspan="1" colspan="1">2.40 (0.76)</td><td rowspan="1" colspan="1">2.33 (0.66)</td><td rowspan="1" colspan="1">2.44 (0.68)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;End-exercise</td><td rowspan="1" colspan="1">2.15 (0.70)</td><td rowspan="1" colspan="1">2.03 (0.62)</td><td rowspan="1" colspan="1">2.13 (0.64)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Mean (SD) breathing discomfort at end-exercise, Borg
units</td><td rowspan="1" colspan="1">6.5 (2.4)</td><td rowspan="1" colspan="1">6.3 (2.8)</td><td rowspan="1" colspan="1">6.6 (2.6)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) leg discomfort at end-exercise, Borg units</td><td rowspan="1" colspan="1">6.5 (2.7)</td><td rowspan="1" colspan="1">6.3 (2.9)</td><td rowspan="1" colspan="1">6.4 (2.9)</td></tr><tr><td colspan="4" rowspan="1">Locus of symptom limitation, <italic>n</italic>
(%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Breathing discomfort</td><td rowspan="1" colspan="1">43 (32.6)</td><td rowspan="1" colspan="1">49 (36.8)</td><td rowspan="1" colspan="1">41 (29.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Breathing/leg discomfort</td><td rowspan="1" colspan="1">56 (42.4)</td><td rowspan="1" colspan="1">53 (39.8)</td><td rowspan="1" colspan="1">59 (42.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Leg discomfort</td><td rowspan="1" colspan="1">32 (24.2)</td><td rowspan="1" colspan="1">28 (21.1)</td><td rowspan="1" colspan="1">37 (26.6)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn7-1753465818755091"><p>CWRCE, constant work-rate cycle ergometry; EET, exercise endurance
time; IC, inspiratory capacity; O, olodaterol; SD, standard
deviation; T, tiotropium.</p></fn></table-wrap-foot></table-wrap><p>A total of 165 patients were included in the ESWT subgroup. Baseline patient
characteristics and exercise-specific characteristics for the ESWT subgroup are
shown in <xref ref-type="table" rid="table1-1753465818755091">Tables 1</xref>
and <xref ref-type="table" rid="table3-1753465818755091">3</xref>, respectively.
Baseline characteristics were generally well balanced across treatment
groups.</p><table-wrap id="table3-1753465818755091" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Baseline endurance shuttle walk test characteristics (endurance shuttle
walk test subgroup, <italic>n</italic> = 165).</p></caption><alternatives><graphic xlink:href="10.1177_1753465818755091-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 50)</th><th align="left" rowspan="1" colspan="1">T/O 2.5/5 &#x000b5;g (<italic>n</italic> = 56)</th><th align="left" rowspan="1" colspan="1">T/O 5/5 &#x000b5;g (<italic>n</italic> = 59)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Mean (SD) baseline EET, s</td><td rowspan="1" colspan="1">346.3 (186.5)</td><td rowspan="1" colspan="1">366.7 (206.0)</td><td rowspan="1" colspan="1">373.7 (217.1)</td></tr><tr><td rowspan="1" colspan="1">Median (minimum, maximum) baseline EET, s</td><td rowspan="1" colspan="1">320.0 (91, 792)</td><td rowspan="1" colspan="1">315.5 (85, 830)</td><td rowspan="1" colspan="1">317.0 (88, 872)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) breathing discomfort at end-exercise, Borg
units</td><td rowspan="1" colspan="1">6.4 (2.9)</td><td rowspan="1" colspan="1">6.5 (2.8)</td><td rowspan="1" colspan="1">6.9 (2.4)</td></tr><tr><td rowspan="1" colspan="1">Mean (SD) leg discomfort at end-exercise, Borg units</td><td rowspan="1" colspan="1">5.6 (3.2)</td><td rowspan="1" colspan="1">5.0 (3.3)</td><td rowspan="1" colspan="1">5.3 (3.5)</td></tr><tr><td colspan="4" rowspan="1">Locus of symptom limitation, <italic>n</italic>
(%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Breathing discomfort</td><td rowspan="1" colspan="1">27 (54.0)</td><td rowspan="1" colspan="1">33 (58.9)</td><td rowspan="1" colspan="1">35 (59.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Breathing/leg discomfort</td><td rowspan="1" colspan="1">13 (26.0)</td><td rowspan="1" colspan="1">9 (16.1)</td><td rowspan="1" colspan="1">14 (23.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Leg discomfort</td><td rowspan="1" colspan="1">10 (20.0)</td><td rowspan="1" colspan="1">14 (25.0)</td><td rowspan="1" colspan="1">10 (16.9)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn8-1753465818755091"><p>EET, exercise endurance time; O, olodaterol; SD, standard deviation;
T, tiotropium.</p></fn></table-wrap-foot></table-wrap><p>Two patients had an EET during CWRCE at baseline of &#x0003e;25 min (i.e. screen
failure); 11 patients had an EET during ESWT at baseline of &#x0003e;15 min (i.e. not
included in the ESWT substudy, but continued in the main study).</p></sec><sec id="section18-1753465818755091"><title>Constant work-rate cycle ergometry (full analysis set)</title><p>Common baseline geometric mean EET [standard error (SE)] during CWRCE was 443.0
(12.4) s. Geometric mean (SE) EET during CWRCE at week 12 (primary endpoint) was
463.6 (18.8) s for placebo, 503.6 (19.6) s for tiotropium/olodaterol 2.5/5 &#x000b5;g,
and 527.5 (20.2) s for tiotropium/olodaterol 5/5 &#x000b5;g, with a statistically
significant increase of 13.8% compared with placebo for tiotropium/olodaterol
5/5 &#x000b5;g (<italic>p</italic> = 0.02) and an increase of 8.6% compared with placebo
for tiotropium/olodaterol 2.5/5 &#x000b5;g (<italic>p</italic> = 0.14) (<xref ref-type="fig" rid="fig3-1753465818755091">Figure 3</xref>). Since the
comparison for tiotropium/olodaterol 2.5/5 &#x000b5;g compared with placebo did not
reach statistical significance, subsequent hypothesis tests within the step-down
hypothesis-testing strategy are considered descriptive rather than confirmatory
(nominal <italic>p</italic> values).</p><fig id="fig3-1753465818755091" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Geometric mean exercise endurance time during constant work-rate cycle
ergometry after 6 and 12 weeks.</p><p><sup>*</sup>Geometric mean results are reported as the primary analysis
based on log<sub>10</sub>-transformed data; week 6 data are not included
in hierarchical testing sequence and should be considered descriptive
only.</p><p>Common geometric mean baseline EET: 443.0 s.</p><p>Placebo, <italic>n</italic> = 121; T/O 2.5/5 &#x003bc;g, <italic>n</italic> =
129; T/O 5/5 &#x003bc;g, <italic>n</italic> = 135.</p><p>EET, exercise endurance time; O, olodaterol; SE, standard error; T,
tiotropium.</p></caption><graphic xlink:href="10.1177_1753465818755091-fig3"/></fig><p>Geometric mean (SE) EET at week 6 was 427.7 (17.1) s for placebo, 522.3 (20.2) s
for tiotropium/olodaterol 2.5/5 &#x000b5;g, and 525.6 (20.0) s for tiotropium/olodaterol
5/5 &#x000b5;g, with a 22.9% increase compared with placebo for tiotropium/olodaterol
5/5 &#x000b5;g (nominal <italic>p</italic> = 0.0002) and a 22.1% increase compared with
placebo for tiotropium/olodaterol 2.5/5 &#x000b5;g (nominal <italic>p</italic> = 0.0004)
(<xref ref-type="fig" rid="fig3-1753465818755091">Figure 3</xref>).</p><p>The common mean IC values at baseline were: pre-exercise, 2397 ml; isotime, 2131
ml; and end-exercise, 2111 ml. Mean IC increased at pre-exercise, isotime, and
end-exercise for both tiotropium/olodaterol doses compared with placebo at weeks
6 and 12 (<xref ref-type="fig" rid="fig4-1753465818755091">Figure 4a</xref>)
(nominal <italic>p</italic> &#x0003c; 0.05 at all time points for
tiotropium/olodaterol 2.5/5 and 5/5 &#x000b5;g).</p><fig id="fig4-1753465818755091" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Mean inspiratory capacity (a) and slope of intensity (b) of breathing
discomfort after 12 weeks.</p><p>Mean baseline IC: pre-exercise, 2397 ml; isotime, 2131 ml; end-exercise,
2111 ml.</p><p>T/O 2.5/5 &#x000b5;g <italic>versus</italic> placebo, <italic>p</italic> =
0.0218; T/O 5/5 &#x000b5;g <italic>versus</italic> placebo, <italic>p</italic> =
0.0598.</p><p>IC, inspiratory capacity; O, olodaterol; SE, standard error; T,
tiotropium.</p></caption><graphic xlink:href="10.1177_1753465818755091-fig4"/></fig><p>The rate of increase in intensity of breathing discomfort (Borg scale) during
exercise [(end of exercise Borg score minus pre-exercise Borg score)/EET] was
lower for both tiotropium/olodaterol doses compared with placebo at weeks 6 and
12 (<xref ref-type="fig" rid="fig4-1753465818755091">Figure 4b</xref>) (nominal
<italic>p</italic> = 0.0218 for tiotropium/olodaterol 2.5/5 &#x000b5;g and
<italic>p</italic> = 0.0598 for tiotropium/olodaterol 5/5 &#x000b5;g at week
12).</p><p>For both tiotropium/olodaterol 2.5/5 and 5/5 &#x000b5;g, increases in FEV<sub>1</sub> and
FVC were observed 1 h after the first dose, and predose and 1 h postdose after 6
and 12 weeks.</p></sec><sec id="section19-1753465818755091"><title>Endurance shuttle walking (ESWT substudy)</title><p>Common baseline geometric mean EET (SE) during ESWT was 311.2 (13.7) s. Geometric
mean (SE) EET during ESWT at week 12 (key secondary endpoint) was 311.4 (22.5) s
for placebo, 377.2 (25.9) s for tiotropium/olodaterol 2.5/5 &#x000b5;g, and 376.4 (25.0)
s for tiotropium/olodaterol 5/5 &#x000b5;g, with an increase of 20.9% compared with
placebo for tiotropium/olodaterol 5/5 &#x000b5;g (nominal <italic>p</italic> = 0.055)
and an increase of 21.1% compared with placebo for tiotropium/olodaterol 2.5/5
&#x000b5;g (nominal <italic>p</italic> = 0.056) (<xref ref-type="fig" rid="fig5-1753465818755091">Figure 5</xref>). One patient on placebo, four
patients on tiotropium/olodaterol 2.5/5 &#x000b5;g, and two patients on
tiotropium/olodaterol 5/5 &#x000b5;g reached test termination (i.e. 20-min
duration).</p><fig id="fig5-1753465818755091" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Geometric mean endurance shuttle walk test endurance time after 6 and 12
weeks in the endurance shuttle walk test subgroup.</p><p><sup>*</sup>Geometric mean results reported as primary analysis based on
log<sub>10</sub>-transformed data; week 6 data are not included in
hierarchical testing sequence and should be considered descriptive
only.</p><p>Common geometric mean baseline ESWT endurance time: 311.2 s.</p><p>Placebo, <italic>n</italic> = 50; T/O 2.5/5 &#x003bc;g, <italic>n</italic> = 56;
T/O 5/5 &#x003bc;g, <italic>n</italic> = 59.</p><p>ESWT, endurance shuttle walk test; O, olodaterol; SE, standard error; T,
tiotropium.</p></caption><graphic xlink:href="10.1177_1753465818755091-fig5"/></fig><p>Geometric mean (SE) ESWT EET at week 6 was 312.0 (22.5) s for placebo, 377.9
(25.8) s for tiotropium/olodaterol 2.5/5 &#x000b5;g, and 376.2 (24.9) s for
tiotropium/olodaterol 5/5 &#x000b5;g, with an increase of 20.6% compared with placebo
for tiotropium/olodaterol 5/5 &#x000b5;g (nominal <italic>p</italic> = 0.058) and an
increase of 21.1% compared with placebo for tiotropium/olodaterol 2.5/5 &#x000b5;g
(nominal <italic>p</italic> = 0.055) (<xref ref-type="fig" rid="fig5-1753465818755091">Figure 5</xref>). No patients on placebo, three
patients on tiotropium/olodaterol 2.5/5 &#x000b5;g, and two patients on tiotropium 5/5
&#x000b5;g reached test termination (i.e. 20-min duration).</p><p>Decreases in the rate of increase in intensity of breathing discomfort (Borg
scale) were observed with both tiotropium/olodaterol doses compared with placebo
at weeks 6 and 12 (<ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">online supplement Figure S2</ext-link>).</p></sec><sec id="section20-1753465818755091"><title>Arithmetic <italic>versus</italic> log<sub>10</sub>-transformed treatment
effects</title><p>To facilitate the interpretation and comparisons across studies, the more
&#x02018;traditional&#x02019; approach based on arithmetic EET data is provided for comparison
to the log<sub>10</sub>-transformed data [online supplement <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">Tables S2 and S3</ext-link> (CWRCE) and <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">Tables S4 and S5</ext-link> (ESWT)]. Using the arithmetic data, there were
25.0 and 14.4% increases in EET during CWRCE with tiotropium/olodaterol 5/5 &#x000b5;g
over placebo at 6 and 12 weeks, respectively.</p></sec><sec id="section21-1753465818755091"><title>Safety (treated set)</title><p>Incidences of AEs, serious AEs, and AEs leading to discontinuation with
tiotropium/olodaterol 2.5/5 and 5/5 &#x000b5;g were similar to placebo (online
supplement <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">Table S6</ext-link>). Most AEs were mild to moderate in severity and not
considered related to study medication by the investigator. The most common AE
was COPD exacerbation, which occurred in 12.1%, 11.3%, and 7.2% of patients
receiving placebo, tiotropium/olodaterol 2.5/5 &#x000b5;g, and tiotropium/olodaterol 5/5
&#x000b5;g, respectively. Two deaths occurred during the study, both in patients
receiving tiotropium/olodaterol 2.5/5 &#x000b5;g: one patient died from lung cancer and
the other from cardio-respiratory arrest (this event did not occur during the
exercise testing). Neither was considered related to study drug by the
investigator.</p></sec></sec><sec sec-type="discussion" id="section22-1753465818755091"><title>Discussion</title><p>In this study, tiotropium/olodaterol 5/5 &#x000b5;g increased EET during CWRCE by 13.8%
compared with placebo after 12 weeks in patients with moderate to severe COPD
(primary endpoint). In the ESWT substudy, a 20.9% increase in EET for
tiotropium/olodaterol 5/5 &#x000b5;g compared with placebo after 12 weeks did not reach
statistical significance (<italic>p</italic> = 0.055).</p><p>The effects of tiotropium/olodaterol on EET during CWRCE in moderate to very severe
COPD have also been investigated in two replicate, double-blind, crossover studies
of 6-week duration (MORACTO<sup>&#x000ae;</sup>).<sup><xref rid="bibr22-1753465818755091" ref-type="bibr">22</xref></sup> Similar to the present study, the MORACTO<sup>&#x000ae;</sup> studies evaluated two
doses of tiotropium/olodaterol (2.5/5 and 5/5 &#x000b5;g), and included placebo, tiotropium
5 &#x000b5;g alone, and olodaterol 5 &#x000b5;g alone as comparator arms to evaluate the efficacy of
tiotropium/olodaterol compared with placebo and its added benefit over the
individual monotherapies. The TORRACTO<sup>&#x000ae;</sup> study was designed to complement
the MORACTO<sup>&#x000ae;</sup> studies by determining whether the effects of
tiotropium/olodaterol compared with placebo on EET during CWRCE were maintained up
to 12 weeks to document the duration of effect.</p><p>EET during CWRCE for tiotropium/olodaterol 5/5 &#x000b5;g was similar at 6 weeks (geometric
mean: 525.6 s) and 12 weeks (geometric mean: 527.5 s), representing 18.6 and 19.1%
improvements, respectively, compared with a baseline geometric mean EET of 443.0 s.
Statistically significant improvements in EET for tiotropium/olodaterol 5/5 &#x000b5;g
compared with placebo were observed after both 6 and 12 weeks, with differences in
response magnitude (22.9% improvement after 6 weeks, 13.8% improvement after 12
weeks) explained by variability in EET in the placebo arm (geometric means of 427.7
and 463.6 s after 6 and 12 weeks, respectively).</p><p>Tiotropium/olodaterol 2.5/5 &#x000b5;g did not achieve statistical significance for the
primary endpoint (EET during CWRCE after 12 weeks). However, several lines of
evidence point to an effect of the lower dose on exercise endurance: (i)
tiotropium/olodaterol 2.5/5 &#x000b5;g significantly improved EET during CWRCE compared with
placebo in both MORACTO<sup>&#x000ae;</sup> studies [26.5% (<italic>p</italic> &#x0003c; 0.0001)
and 12.1% (<italic>p</italic> = 0.0003)]; (ii) there was a nominally significant
improvement in EET during CWRCE after 6 weeks (22.1%, nominal <italic>p</italic> =
0.0004) in the present study; (iii) in <italic>post hoc</italic> analysis, change
from baseline in EET during CWRCE after 6 and 12 weeks was nominally
significant.</p><p>Endurance time during ESWT has been used as an outcome measure in pulmonary
rehabilitation studies for many years.<sup><xref rid="bibr23-1753465818755091" ref-type="bibr">23</xref></sup> Recently, there has been increased attention on ESWT as a methodology to
evaluate bronchodilator efficacy. Early single-center studies provided promising
results, showing that endurance time during ESWT offered a sensitive test to assess
bronchodilation in patients with COPD.<sup><xref rid="bibr7-1753465818755091" ref-type="bibr">7</xref>,<xref rid="bibr9-1753465818755091" ref-type="bibr">9</xref><xref rid="bibr10-1753465818755091" ref-type="bibr"/>&#x02013;<xref rid="bibr11-1753465818755091" ref-type="bibr">11</xref></sup> However, multicenter,
multinational studies have value in supporting generalizability, as has been done
for CWRCE.<sup><xref rid="bibr21-1753465818755091" ref-type="bibr">21</xref>,<xref rid="bibr24-1753465818755091" ref-type="bibr">24</xref><xref rid="bibr25-1753465818755091" ref-type="bibr"/><xref rid="bibr26-1753465818755091" ref-type="bibr"/><xref rid="bibr27-1753465818755091" ref-type="bibr"/><xref rid="bibr28-1753465818755091" ref-type="bibr"/><xref rid="bibr29-1753465818755091" ref-type="bibr"/><xref rid="bibr30-1753465818755091" ref-type="bibr"/><xref rid="bibr31-1753465818755091" ref-type="bibr"/>&#x02013;<xref rid="bibr32-1753465818755091" ref-type="bibr">32</xref></sup> At the time of study
initiation in March 2012, there were no published studies using a multicenter trial
with ESWT to evaluate the effects of pharmacotherapy in COPD. The first multicenter
study was conducted in 2010&#x02013;2011, with results published in 2013.<sup><xref rid="bibr33-1753465818755091" ref-type="bibr">33</xref></sup> Two replicate, multicenter studies were conducted in 2011&#x02013;2012, with results
published in 2014.<sup><xref rid="bibr34-1753465818755091" ref-type="bibr">34</xref></sup></p><p>The present study adds to the knowledge about the use of ESWT to assess the effects
of bronchodilation on exercise capacity in patients with COPD in a multicenter
setting. Based on the methodologic concerns regarding the transition from a
single-center to a multicenter setting, a high degree of attention was placed on
trial oversight with respect to the training and monitoring of the ESWT. Details of
these quality control efforts are described in the <ext-link ext-link-type="uri" xlink:href="http://journals.sagepub.com/doi/suppl/10.1177/1753465818755091">online supplement</ext-link> as reference for other researchers interested in
conducting multicenter studies using ESWT. The ESWT performed well in this trial;
the lack of a learning effect in the placebo arm (i.e. similar EET in placebo arm at
baseline and after 6 and 12 weeks) suggests that study participants were able to
produce reproducible exercise tests. Future efforts to determine the minimal quality
control criteria in multicenter ESWT studies are warranted.</p><p>Although statistical significance was just missed (<italic>p</italic> = 0.055), the
observed 20% improvement in EET in ESWT at 6 and 12 weeks with both doses of
tiotropium/olodaterol is beyond the proposed minimally important difference for this parameter.<sup><xref rid="bibr35-1753465818755091" ref-type="bibr">35</xref></sup> With the recognition that the ESWT has a fixed test termination of 20 min,<sup><xref rid="bibr8-1753465818755091" ref-type="bibr">8</xref></sup> study eligibility criteria included a baseline EET of &#x0003c;15 min to allow for
sufficient post-treatment endurance times within the 20-min test. This was the case
for the majority of patients, but one patient in the placebo group, four patients in
the tiotropium/olodaterol 2.5/5 &#x000b5;g group, and two patients in the
tiotropium/olodaterol 5/5 &#x000b5;g group reached the 20-min test termination time point
during ESWT after 12 weeks (i.e. did not reach symptom limitation). This may have
contributed to reducing the statistical power of the study. A more recent study
(PHYSACTO<sup>&#x000ae;</sup>), with a greater sample size than the present study (65&#x02013;72
patients per treatment arm), has shown significant improvements in EET during ESWT
after 8 weeks of treatment with tiotropium/olodaterol compared with placebo in
patients who participated in a self-management behavior-change program (29%
increase, <italic>p</italic> &#x0003c; 0.01).<sup><xref rid="bibr23-1753465818755091" ref-type="bibr">23</xref></sup></p><p>An important methodologic consideration in relation to the current trial is that
statistical analyses were performed on log<sub>10</sub>-transformed endurance time
data. Although these analyses are justified in that endurance time during constant
work-rate exercise is asymmetrically distributed around the mean, with a significant
skew towards long EETs,<sup><xref rid="bibr20-1753465818755091" ref-type="bibr">20</xref>,<xref rid="bibr36-1753465818755091" ref-type="bibr">36</xref></sup> this approach complicates comparisons with previous trials.</p><p>For the purpose of facilitating comparisons across studies, we also report arithmetic
mean treatment effects of tiotropium/olodaterol <italic>versus</italic> placebo,
which ranged from 118 s to 124 s, or ~25% increase over placebo for CWRCE at week 6.
Despite expected differences in adjusted mean values between untransformed and
log<sub>10</sub>-transformed approaches, relative (%) increases in EET for
active treatment arms <italic>versus</italic> placebo and the respective statistical
significances were very similar for the two statistical approaches, supporting the
robustness of the findings.</p><p>The improvements in EET <italic>versus</italic> placebo are consistent with what is
expected from single and dual long-acting bronchodilators.<sup><xref rid="bibr21-1753465818755091" ref-type="bibr">21</xref>,<xref rid="bibr25-1753465818755091" ref-type="bibr">25</xref>,<xref rid="bibr28-1753465818755091" ref-type="bibr">28</xref>,<xref rid="bibr32-1753465818755091" ref-type="bibr">32</xref>,<xref rid="bibr36-1753465818755091" ref-type="bibr">36</xref>,<xref rid="bibr37-1753465818755091" ref-type="bibr">37</xref></sup> Also, increases in EET in
CWRCE with active treatments in the present study were beyond the estimated range
for a clinically meaningful difference, compared with placebo, of 46&#x02013;105 s for
endurance time, as proposed by the European Respiratory Society task force on
outcomes in COPD.<sup><xref rid="bibr38-1753465818755091" ref-type="bibr">38</xref></sup> Despite not reaching formal statistical significance, the increase in EET
during ESWT, averaging 81&#x02013;88 s or 21% at week 6, compared advantageously with
previous publications (121 s, 31% at 3 weeks;<sup><xref rid="bibr39-1753465818755091" ref-type="bibr">39</xref></sup> 47 s, 15% at 12 weeks<sup><xref rid="bibr34-1753465818755091" ref-type="bibr">34</xref></sup>). The increase in EET during ESWT with tiotropium/olodaterol was also beyond
the proposed clinically meaningful difference.<sup><xref rid="bibr35-1753465818755091" ref-type="bibr">35</xref></sup></p><p>The primary evidence of clinical efficacy to support the health authority approval of
tiotropium/olodaterol 5/5 &#x000b5;g was based on the observed effects on lung function
(FEV<sub>1</sub>) and health-related quality of life (St. George&#x02019;s Respiratory
Questionnaire) in the 52-week TONADO<sup>&#x000ae;</sup> studies. However, exercise capacity
has been recommended as an important additional clinical outcome in COPD
pharmacologic trials.<sup><xref rid="bibr40-1753465818755091" ref-type="bibr">40</xref></sup> The results from the present TORRACTO<sup>&#x000ae;</sup> study, as well as from the
previously reported MORACTO<sup>&#x000ae;</sup> studies, extend the clinical evaluation of
tiotropium/olodaterol 5/5 &#x000b5;g, and provide a more complete characterization of
therapeutic benefit at the impairment-disability interface. The results show that
the primary effects of tiotropium/olodaterol 5/5 &#x000b5;g on lung function lead to
clinically meaningful downstream improvements in the capacity to perform different
types of exercise (cycling, walking), which is arguably a more meaningful outcome to
patients with COPD, who struggle to perform daily activities due to exertional
breathlessness.</p></sec><sec sec-type="conclusions" id="section23-1753465818755091"><title>Conclusion</title><p>Tiotropium/olodaterol 5/5 &#x000b5;g improved endurance time during cycle ergometry
<italic>versus</italic> placebo, with a strong tendency to also improve walking
endurance.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><caption><title>Supplementary material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="TORRACTO_online_supplementary_material_12_Dec_highlighted.pdf" orientation="portrait" id="d35e1592" position="anchor"/></supplementary-material></sec></body><back><ack><p>The authors meet the criteria for authorship as recommended by the International
Committee of Medical Journal Editors. They take full responsibility for the scope,
direction, content of, and editorial decisions relating to, the manuscript; they
were involved at all stages of development, and have approved the submitted
manuscript. The authors received no compensation related to the development of the
manuscript. This work was supported by Boehringer Ingelheim International GmbH.
Medical writing assistance was provided by Rob Kite, BSc, of Complete HealthVizion,
which was contracted and compensated by Boehringer Ingelheim Pharma GmbH &#x00026; Co.
KG.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This work was funded by Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG.</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> FM has received research support and speaker fees from AstraZeneca, Novartis, and
Grifols, and research support, advisory board participation, and speaker fees
from Boehringer Ingelheim and GlaxoSmithKline. DO&#x02019;D has received research grants
<italic>via</italic> his institution from AstraZeneca, Boehringer Ingelheim,
and GlaxoSmithKline, and has served on speaker bureaus, consultation panels, and
advisory boards for Almirall, AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Novartis, and Pfizer. JBGI has nothing to disclose. A-MK has
received payment for lectures from Boehringer Ingelheim, AstraZeneca, and
Novartis, and her institution has received compensation for the conduct of
clinical studies from AstraZeneca, Boehringer Ingelheim, Roche, GlaxoSmithKline,
Novartis, Chiesi, Takeda, Bayer, Sterna Biologicals, Johnson &#x00026; Johnson, and
Sanofi. DS has received personal fees from Apellis, Cipla, Genentech,
Peptinnovate, and SkyePharma, and grants and personal fees from AstraZeneca,
Boehringer Ingelheim, Chiesi, Glenmark, Merck, Mundipharma, Novartis, Pfizer,
Pulmatrix, Teva, Theravance, and Verona. RC has received personal fees from
Sunovion and Theravance, and grants and personal fees from Boehringer Ingelheim,
AstraZeneca, and Astellas. AH, KT, and YZ are employees of Boehringer
Ingelheim.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-1753465818755091"><label>1</label><mixed-citation publication-type="journal">
<collab>American Thoracic Society and American College of Chest
Physicians</collab>. <article-title>ATS/ACCP statement on cardiopulmonary
exercise testing</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2003</year>; <volume>167</volume>:
<fpage>211</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">12524257</pub-id></mixed-citation></ref><ref id="bibr2-1753465818755091"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borel</surname><given-names>B</given-names></name><name><surname>Provencher</surname><given-names>S</given-names></name><name><surname>Saey</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Responsiveness of various exercise-testing
protocols to therapeutic interventions in COPD</article-title>. <source>Pulm
Med</source>
<year>2013</year>; <volume>2013</volume>:
<fpage>410748</fpage>.<pub-id pub-id-type="pmid">23431439</pub-id></mixed-citation></ref><ref id="bibr3-1753465818755091"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Van&#x02018;t Hul</surname><given-names>A</given-names></name><name><surname>Gosselink</surname><given-names>R</given-names></name><name><surname>Kwakkel</surname><given-names>G</given-names></name></person-group>
<article-title>Constant-load cycle endurance performance:
test-retest reliability and validity in patients with COPD</article-title>.
<source>J Cardiopulm Rehabil</source>
<year>2003</year>; <volume>23</volume>:
<fpage>143</fpage>&#x02013;<lpage>150</lpage>.<pub-id pub-id-type="pmid">12668937</pub-id></mixed-citation></ref><ref id="bibr4-1753465818755091"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liesker</surname><given-names>JJW</given-names></name><name><surname>van De Velde</surname><given-names>V</given-names></name><name><surname>Meysman</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of formoterol (Oxis<sup>&#x000ae;</sup>
Turbuhaler<sup>&#x000ae;</sup>) and ipratropium on exercise capacity in patients
with COPD</article-title>. <source>Respir Med</source>
<year>2002</year>; <volume>96</volume>:
<fpage>559</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">12195835</pub-id></mixed-citation></ref><ref id="bibr5-1753465818755091"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>S.</given-names></name></person-group>
<article-title>Which is the best exercise test to assess therapeutic
intervention in COPD?</article-title>
<source>Chron Respir Dis</source>
<year>2008</year>; <volume>5</volume>:
<fpage>3</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18303095</pub-id></mixed-citation></ref><ref id="bibr6-1753465818755091"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aguilaniu</surname><given-names>B.</given-names></name></person-group>
<article-title>Impact of bronchodilator therapy on exercise tolerance in
COPD</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>
<year>2010</year>; <volume>5</volume>:
<fpage>57</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">20463947</pub-id></mixed-citation></ref><ref id="bibr7-1753465818755091"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Waterman</surname><given-names>LA</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Advantages of endurance treadmill walking
compared with cycling to assess bronchodilator therapy</article-title>.
<source>Chest</source>
<year>2010</year>; <volume>137</volume>:
<fpage>1354</fpage>&#x02013;<lpage>1361</lpage>.<pub-id pub-id-type="pmid">20040610</pub-id></mixed-citation></ref><ref id="bibr8-1753465818755091"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Revill</surname><given-names>SM</given-names></name><name><surname>Morgan</surname><given-names>MDL</given-names></name><name><surname>Singh</surname><given-names>SJ</given-names></name><etal>et al</etal></person-group>
<article-title>The endurance shuttle walk: a new field test for
the assessment of endurance capacity in chronic obstructive pulmonary
disease</article-title>. <source>Thorax</source>
<year>1999</year>; <volume>54</volume>:
<fpage>213</fpage>&#x02013;<lpage>222</lpage>.<pub-id pub-id-type="pmid">10325896</pub-id></mixed-citation></ref><ref id="bibr9-1753465818755091"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouillard</surname><given-names>C</given-names></name><name><surname>Pepin</surname><given-names>V</given-names></name><name><surname>Milot</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Endurance shuttle walking test: responsiveness
to salmeterol in COPD</article-title>. <source>Eur Respir J</source>
<year>2008</year>; <volume>31</volume>:
<fpage>579</fpage>&#x02013;<lpage>584</lpage>.<pub-id pub-id-type="pmid">18057052</pub-id></mixed-citation></ref><ref id="bibr10-1753465818755091"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pepin</surname><given-names>V</given-names></name><name><surname>Saey</surname><given-names>D</given-names></name><name><surname>Whittom</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Walking versus cycling: sensitivity to
bronchodilation in chronic obstructive pulmonary disease</article-title>.
<source>Am J Respir Crit Care Med</source>
<year>2005</year>; <volume>172</volume>:
<fpage>1517</fpage>&#x02013;<lpage>1522</lpage>.<pub-id pub-id-type="pmid">16166613</pub-id></mixed-citation></ref><ref id="bibr11-1753465818755091"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pepin</surname><given-names>V</given-names></name><name><surname>Brodeur</surname><given-names>J</given-names></name><name><surname>Lacasse</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Six-minute walking versus shuttle walking:
responsiveness to bronchodilation in chronic obstructive pulmonary
disease</article-title>. <source>Thorax</source>
<year>2007</year>; <volume>62</volume>:
<fpage>291</fpage>&#x02013;<lpage>298</lpage>.<pub-id pub-id-type="pmid">17099077</pub-id></mixed-citation></ref><ref id="bibr12-1753465818755091"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pepin</surname><given-names>V</given-names></name><name><surname>Laviolette</surname><given-names>L</given-names></name><name><surname>Brouillard</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Significance of changes in endurance shuttle
walking performance</article-title>. <source>Thorax</source>
<year>2011</year>; <volume>66</volume>:
<fpage>115</fpage>&#x02013;<lpage>120</lpage>.<pub-id pub-id-type="pmid">21148135</pub-id></mixed-citation></ref><ref id="bibr13-1753465818755091"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Standardisation of spirometry</article-title>.
<source>Eur Respir J</source>
<year>2005</year>; <volume>26</volume>:
<fpage>319</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">16055882</pub-id></mixed-citation></ref><ref id="bibr14-1753465818755091"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Webb</surname><given-names>KA.</given-names></name></person-group>
<article-title>Exertional breathlessness in patients with chronic airflow
limitation. The role of lung hyperinflation</article-title>. <source>Am Rev
Respir Dis</source>
<year>1993</year>; <volume>148</volume>:
<fpage>1351</fpage>&#x02013;<lpage>1357</lpage>.<pub-id pub-id-type="pmid">8239175</pub-id></mixed-citation></ref><ref id="bibr15-1753465818755091"><label>15</label><mixed-citation publication-type="journal">
<collab>European Respiratory Society Task Force on Standardization of Clinical
Exercise Testing</collab>. <article-title>Clinical exercise testing with
reference to lung diseases: indications, standardization and interpretation
strategies</article-title>. <source>Eur Respir J</source>
<year>1997</year>; <volume>10</volume>:
<fpage>2662</fpage>&#x02013;<lpage>2689</lpage>.<pub-id pub-id-type="pmid">9426113</pub-id></mixed-citation></ref><ref id="bibr16-1753465818755091"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Lam</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>KA.</given-names></name></person-group>
<article-title>Measurement of symptoms, lung hyperinflation, and endurance
during exercise in chronic obstructive pulmonary disease</article-title>.
<source>Am J Respir Crit Care Med</source>
<year>1998</year>; <volume>158</volume>:
<fpage>1557</fpage>&#x02013;<lpage>1565</lpage>.<pub-id pub-id-type="pmid">9817708</pub-id></mixed-citation></ref><ref id="bibr17-1753465818755091"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>SJ</given-names></name><name><surname>Morgan</surname><given-names>MDL</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Development of a shuttle walking test of
disability in patients with chronic airways obstruction</article-title>.
<source>Thorax</source>
<year>1992</year>; <volume>47</volume>:
<fpage>1019</fpage>&#x02013;<lpage>1024</lpage>.<pub-id pub-id-type="pmid">1494764</pub-id></mixed-citation></ref><ref id="bibr18-1753465818755091"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hareendran</surname><given-names>A</given-names></name><name><surname>Leidy</surname><given-names>NK</given-names></name><name><surname>Monz</surname><given-names>BU</given-names></name><etal>et al</etal></person-group>
<article-title>Proposing a standardized method for evaluating
patient report of the intensity of dyspnea during exercise testing in
COPD</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>
<year>2012</year>; <volume>7</volume>:
<fpage>345</fpage>&#x02013;<lpage>355</lpage>.<pub-id pub-id-type="pmid">22745534</pub-id></mixed-citation></ref><ref id="bibr19-1753465818755091"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>AL</given-names></name><name><surname>Killian</surname><given-names>KJ</given-names></name><name><surname>Summers</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Symptom intensity and subjective limitation to
exercise in patients with cardiorespiratory disorders</article-title>.
<source>Chest</source>
<year>1996</year>; <volume>110</volume>:
<fpage>1255</fpage>&#x02013;<lpage>1263</lpage>.<pub-id pub-id-type="pmid">8915230</pub-id></mixed-citation></ref><ref id="bibr20-1753465818755091"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Travers</surname><given-names>J</given-names></name><name><surname>Webb</surname><given-names>KA</given-names></name><etal>et al</etal></person-group>
<article-title>Reliability of ventilatory parameters during
cycle ergometry in multicentre trials in COPD</article-title>. <source>Eur
Respir J</source>
<year>2009</year>; <volume>34</volume>:
<fpage>866</fpage>&#x02013;<lpage>874</lpage>.<pub-id pub-id-type="pmid">19282342</pub-id></mixed-citation></ref><ref id="bibr21-1753465818755091"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Hamilton</surname><given-names>A</given-names></name><name><surname>Marciniuk</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Improvements in symptom-limited exercise
performance over 8 h with once-daily tiotropium in patients with
COPD</article-title>. <source>Chest</source>
<year>2005</year>; <volume>128</volume>:
<fpage>1168</fpage>&#x02013;<lpage>1178</lpage>.<pub-id pub-id-type="pmid">16162703</pub-id></mixed-citation></ref><ref id="bibr22-1753465818755091"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>D</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Firth</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of combined tiotropium/olodaterol on
inspiratory capacity and exercise endurance in COPD</article-title>.
<source>Eur Respir J</source>
<year>2017</year>; <volume>49</volume> DOI: <pub-id pub-id-type="doi">10.1183/13993003.01348-2016.</pub-id></mixed-citation></ref><ref id="bibr23-1753465818755091"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Troosters</surname><given-names>T</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Maltais</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of 8 and 12 weeks&#x02019; once-daily tiotropium
and olodaterol, alone and combined with exercise training, on exercise
endurance during walking in patients with COPD</article-title>. <source>Eur
Respir J</source>
<year>2016</year>; <volume>48</volume>: <fpage>PA976</fpage>.</mixed-citation></ref><ref id="bibr24-1753465818755091"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Beck</surname><given-names>E</given-names></name><name><surname>Gahlemann</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Dose-finding study of 4-week, once-daily
treatment with olodaterol, a novel long-acting &#x003b2;2-agonist, in patients with
asthma</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2012</year>; <volume>185</volume>: abstract A2764.</mixed-citation></ref><ref id="bibr25-1753465818755091"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Korn</surname><given-names>S</given-names></name><name><surname>Beier</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of QVA149 on lung volumes and exercise
tolerance in COPD patients: the BRIGHT study</article-title>. <source>Respir
Med</source>
<year>2014</year>; <volume>108</volume>:
<fpage>584</fpage>&#x02013;<lpage>592</lpage>.<pub-id pub-id-type="pmid">24534204</pub-id></mixed-citation></ref><ref id="bibr26-1753465818755091"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Moroni-Zentgraf</surname><given-names>P</given-names></name><name><surname>Ablinger</surname><given-names>O</given-names></name><etal>et al</etal></person-group>
<article-title>Tiotropium Respimat<sup>&#x000ae;</sup> in asthma: a
double-blind, randomised, dose-ranging study in adult patients with moderate
asthma</article-title>. <source>Respir Res</source>
<year>2014</year>; <volume>15</volume>: <fpage>61</fpage>.<pub-id pub-id-type="pmid">24890738</pub-id></mixed-citation></ref><ref id="bibr27-1753465818755091"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Watz</surname><given-names>H</given-names></name><name><surname>Puente-Maestu</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Aclidinium improves exercise endurance, dyspnea,
lung hyperinflation, and physical activity in patients with COPD: a
randomized, placebo-controlled, crossover trial</article-title>. <source>BMC
Pulm Med</source>
<year>2014</year>; <volume>14</volume>: <fpage>209</fpage>.<pub-id pub-id-type="pmid">25539654</pub-id></mixed-citation></ref><ref id="bibr28-1753465818755091"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Di Scala</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Once-daily NVA237 improves exercise tolerance
from the first dose in patients with COPD: the GLOW3 trial</article-title>.
<source>Int J Chron Obstruct Pulmon Dis</source>
<year>2012</year>; <volume>7</volume>:
<fpage>503</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">22973092</pub-id></mixed-citation></ref><ref id="bibr29-1753465818755091"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Voduc</surname><given-names>N</given-names></name><name><surname>Fitzpatrick</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of salmeterol on the ventilatory response
to exercise in chronic obstructive pulmonary disease</article-title>.
<source>Eur Respir J</source>
<year>2004</year>; <volume>24</volume>:
<fpage>86</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">15293609</pub-id></mixed-citation></ref><ref id="bibr30-1753465818755091"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Parker</surname><given-names>CM.</given-names></name></person-group>
<article-title>COPD exacerbations &#x000b7; 3: pathophysiology</article-title>.
<source>Thorax</source>
<year>2006</year>; <volume>61</volume>:
<fpage>354</fpage>&#x02013;<lpage>361</lpage>.<pub-id pub-id-type="pmid">16565268</pub-id></mixed-citation></ref><ref id="bibr31-1753465818755091"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Vincken</surname><given-names>W</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of indacaterol on exercise endurance and
lung hyperinflation in COPD</article-title>. <source>Respir Med</source>
<year>2011</year>; <volume>105</volume>:
<fpage>1030</fpage>&#x02013;<lpage>1036</lpage>.<pub-id pub-id-type="pmid">21498063</pub-id></mixed-citation></ref><ref id="bibr32-1753465818755091"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Aclidinium bromide improves exercise endurance
and lung hyperinflation in patients with moderate to severe
COPD</article-title>. <source>Respir Med</source>
<year>2011</year>; <volume>105</volume>:
<fpage>580</fpage>&#x02013;<lpage>587</lpage>.<pub-id pub-id-type="pmid">21183326</pub-id></mixed-citation></ref><ref id="bibr33-1753465818755091"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Pepin</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of fluticasone propionate/salmeterol plus
tiotropium versus tiotropium on walking endurance in COPD</article-title>.
<source>Eur Respir J</source>
<year>2013</year>; <volume>42</volume>:
<fpage>539</fpage>&#x02013;<lpage>541</lpage>.<pub-id pub-id-type="pmid">23904549</pub-id></mixed-citation></ref><ref id="bibr34-1753465818755091"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Donald</surname><given-names>AC</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of a combination of
umeclidinium/vilanterol on exercise endurance in patients with chronic
obstructive pulmonary disease: two randomized, double-blind clinical
trials</article-title>. <source>Ther Adv Respir Dis</source>
<year>2014</year>; <volume>8</volume>:
<fpage>169</fpage>&#x02013;<lpage>181</lpage>.<pub-id pub-id-type="pmid">25452426</pub-id></mixed-citation></ref><ref id="bibr35-1753465818755091"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borel</surname><given-names>B</given-names></name><name><surname>Pepin</surname><given-names>V</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><etal>et al</etal></person-group>
<article-title>Prospective validation of the endurance shuttle
walking test in the context of bronchodilation in COPD</article-title>.
<source>Eur Respir J</source>
<year>2014</year>; <volume>44</volume>:
<fpage>1166</fpage>&#x02013;<lpage>1176</lpage>.<pub-id pub-id-type="pmid">25186261</pub-id></mixed-citation></ref><ref id="bibr36-1753465818755091"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Fl&#x000fc;ge</surname><given-names>T</given-names></name><name><surname>Gerken</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Effects of tiotropium on lung hyperinflation,
dyspnoea and exercise tolerance in COPD</article-title>. <source>Eur Respir
J</source>
<year>2004</year>; <volume>23</volume>:
<fpage>832</fpage>&#x02013;<lpage>840</lpage>.<pub-id pub-id-type="pmid">15218994</pub-id></mixed-citation></ref><ref id="bibr37-1753465818755091"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Donnell</surname><given-names>DE</given-names></name><name><surname>Sciurba</surname><given-names>F</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Effect of fluticasone propionate/salmeterol on
lung hyperinflation and exercise endurance in COPD</article-title>.
<source>Chest</source>
<year>2006</year>; <volume>130</volume>:
<fpage>647</fpage>&#x02013;<lpage>656</lpage>.<pub-id pub-id-type="pmid">16963658</pub-id></mixed-citation></ref><ref id="bibr38-1753465818755091"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Puente-Maestu</surname><given-names>L</given-names></name><name><surname>Palange</surname><given-names>P</given-names></name><name><surname>Casaburi</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Use of exercise testing in the evaluation of
interventional efficacy: an official ERS statement</article-title>.
<source>Eur Respir J</source>
<year>2016</year>; <volume>47</volume>:
<fpage>429</fpage>&#x02013;<lpage>460</lpage>.<pub-id pub-id-type="pmid">26797036</pub-id></mixed-citation></ref><ref id="bibr39-1753465818755091"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>B&#x000e9;dard</surname><given-names>ME</given-names></name><name><surname>Brouillard</surname><given-names>C</given-names></name><name><surname>Pepin</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Tiotropium improves walking endurance in
COPD</article-title>. <source>Eur Respir J</source>
<year>2012</year>; <volume>39</volume>:
<fpage>265</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">21700602</pub-id></mixed-citation></ref><ref id="bibr40-1753465818755091"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><etal>et al</etal></person-group>
<article-title>Outcomes for COPD pharmacological trials: from
lung function to biomarkers</article-title>. <source>Eur Respir J</source>
<year>2008</year>; <volume>31</volume>:
<fpage>416</fpage>&#x02013;<lpage>469</lpage>.<pub-id pub-id-type="pmid">18238951</pub-id></mixed-citation></ref></ref-list></back></article>